Pacira BioSciences Reports Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Pacira Pharmaceuticals (PCRX) PT Raised to $62 at BMO Capital
November 5, 2021 6:49 AM EDTBMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $62.00 (from $60.00) while maintaining a Market Perform rating.
The analyst commented, "3Q Exparel sales preannounced 10/11 had been weaker-than-expected from continued COVID headwinds, but PCRX's optimistic in recovering procedure trends... More
Pacira Pharma (PCRX) Tops Q3 EPS by 7c
November 3, 2021 8:06 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.07 better than the analyst estimate of $0.65. Revenue for the quarter came in at $127.7 million versus the consensus estimate of $130.38 million.
For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.
... More